After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
A study found no survival differences between high-grade UTUC patients who at the time of radical nephroureterectomy achieved low-grade disease following neoadjuvant chemotherapy and those who had inherently low-stage disease and did not receive chemotherapy.
Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.
Phase 3 trial shows prolonged progression-free survival for atezolizumab plus platinum-based chemotherapy.
Patients who received intravesical BCG instillation following surgery for nonmuscle-invasive bladder cancer had a lower risk of recurrence of upper tract urothelial carcinoma and bladder cancer, a study found.
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
In a small study, single-dose instillation of mitomycin C immediately following therapeutic ureteroscopy for upper tract urothelial carcinoma was associated with an 87% decreased risk of urothelial recurrence.
Larger tumor size and more advanced tumor stage are associated with an increased risk of intravesical recurrence among patients undergoing radical nephroureterectomy for in upper tract urothelial carcinoma.
A combination of pembrolizumab and an antibody-drug conjugate demonstrated a 73% overall response rate in a phase 1/2 clinical trial.
